Effect of Pioglitazone and Metformin Tablets on Sex Hormones Insulin Resistance, Serum Inflammatory Parameters in Patients with Primary Polycystic Ovary Syndrome
CHEN Xiaojun, CHAI Fang, et al
Sanya People's Hospital, Hainan Sanya 572000, China
Abstract:Objective: To investigate the effect of pioglitazone and metformin tablets on sex hormones, insulin resistance, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and tumor necrosis factor-α ( TNF-α) levels in patients with primary polycystic ovary syndrome (PCOS). Methods: A total of 97 patients with PCOS admitted to our hospital between January 2018 and October 2020 were analyzed retrospectively. According to the treatment regimens, the patients were divided into study group (47 cases) and control group (50 cases). All were treated with ethinylestradiol cyproterone tablets. On this basis, the control group was treated with metformin tablets, and the study group was treated with pioglitazone and metformin tablets, for 3 months. The curative effect, sex hormones, insulin resistance index, serum hs-CRP, IL-6 and TNF-α levels, and quality of life were compared between the two groups. Results: The total effective rate of treatment in the study group was 93.62%, higher than 78.00% in the control group (P<0.05). After treatment, the levels of luteinizing hormone, testosterone, fasting blood glucose, fasting insulin, insulin resistance index, serum hs-CRP, IL-6 and TNF-α were significantly reduced (P<0.05), and the total quality of life scores were significantly increased (P<0.05). Meanwhile, the difference before and after treatment of luteinizing hormone, testosterone, fasting blood glucose, fasting insulin, insulin resistance index, serum hs-CRP, IL-6, TNF-α and the total quality of life score in the study group were higher than those in the control group (P<0.05). Conclusion: Pioglitazone and metformin tablets are more advantageous than monotherapy in the treatment of primary polycystic ovary syndrome, significantly reducing luteinizing hormone and testosterone levels, improving insulin resistance, regulating inflammatory factors and improving quality of life.
[1] Shang Y,Zhou H,Hu M,et al.Effect of diet on insulin resistance in polycystic ovary syndrome[J].Clin Endocrinol Metab,2020,105(10):425~428. [2] 李萍,张燕,郝苗苗.慢性炎症因子与多囊卵巢综合征发病机制相关性研究进展[J].中国保健营养,2019,29(33):391. [3] Sohaei S,Amani R,Tarrahi MJ,et al.The effects of curcumin supplementation on glycemic status,lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome:a randomized,double-blind,placebo-controlled clinical trial[J].Complement Ther Med,2019,12(47):10220~10221. [4] Ali DE,Shah M,Ali A,et al.Treatment with metformin and combination of metformin plus pioglitazone on serum levels of IL-6 and IL-8 in polycystic ovary syndrome:a randomized clinical trial[J].Horm Metab Res,2019,51(11):714~722. [5] Xue J,Li X,Liu P,et al.Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice[J].Endocr,2019,66(10):859~870. [6] Kim JM,Kim SS,Kim JH,et al.Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy:a randomized,open-label,multicenter,parallel-controlled study[J].Diabetes Metab,2020,44(1):67~77. [7] 中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志,2018,53(1):2~6. [8] 梁娜,张政梅.二甲双胍与吡格列酮对多囊卵巢综合征患者性激素及代谢水平的影响[J].广西医学,2019,41(2):148~152. [9] 赵智瑞,何国丽,林琳,等.胰岛素增敏剂干预对多囊卵巢综合征患者血清和肽素,胰岛素抵抗及BMI的影响[J].中国医师杂志,2020,22(12):1836~1839. [10] Hasan MM,El-Shal AS,Mackawy AMH,et al.Ameliorative effect of combined low dose of pioglitazone and omega-3 on spermatogenesis and steroidogenesis in diabetic rats[J].Cell Biochem,2020,121(2):1524~1540. [11] 黄玉梅,罗静思,曹晓兰,等.PCOS患者血清HSP70,炎症-氧化应激指标表达及与胰岛素抵抗的关系[J].中国妇产科临床杂志,2020,21(3):79~80. [12] Alipourfard I,Datukishvili N,Mikeladze D.TNF-α downregulation modifies insulin receptor substrate 1 (IRS-1) in metabolic signaling of diabetic insulin-resistant hepatocytes[J].Mediators Inflamm,2019,2(4):816~819.